Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.

Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM, PROMISE Study Group

Open source

DOI: 10.1513/annalsats.202507-817oc
Published: 2026 Feb 1
Container: Annals of the American Thoracic Society
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1513/annalsats.202507-817oc,
  title = {Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.},
  author = {Sagel SD and Poore TS and Wagner BD and Xie J and Heltshe SL and Cross M and Bratcher PE and Taylor-Cousar JL and Wilson A and McBennett K and Morgan SJ and Singh PK and Nichols DP and Kelly A and Solomon GM and PROMISE Study Group},
  year = {2026},
  journal = {Annals of the American Thoracic Society},
  doi = {10.1513/annalsats.202507-817oc},
  url = {https://doi.org/10.1513/annalsats.202507-817oc}
}

RIS

TY  - JOUR
TI  - Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
AU  - Sagel SD
AU  - Poore TS
AU  - Wagner BD
AU  - Xie J
AU  - Heltshe SL
AU  - Cross M
AU  - Bratcher PE
AU  - Taylor-Cousar JL
AU  - Wilson A
AU  - McBennett K
AU  - Morgan SJ
AU  - Singh PK
AU  - Nichols DP
AU  - Kelly A
AU  - Solomon GM
AU  - PROMISE Study Group
PY  - 2026
JO  - Annals of the American Thoracic Society
DO  - 10.1513/annalsats.202507-817oc
UR  - https://doi.org/10.1513/annalsats.202507-817oc
ER  -

APA

SD, S., TS, P., BD, W., J, X., SL, H., M, C., PE, B., JL, T., A, W., K, M., SJ, M., PK, S., DP, N., A, K., GM, S., & Group, P. S. (2026). Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.202507-817oc

Source records

pubmed · retrieved 2026-09-26T16:49:01.447Z